Crinetics Pharmaceuticals Revenue and Competitors

Location

$446M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Crinetics Pharmaceuticals's estimated annual revenue is currently $2.4M per year.(i)
  • Crinetics Pharmaceuticals received $63.5M in venture funding in March 2018.
  • Crinetics Pharmaceuticals's estimated revenue per employee is $7,205
  • Crinetics Pharmaceuticals's total funding is $446M.
  • Crinetics Pharmaceuticals's current valuation is $1.1B. (January 2022)

Employee Data

  • Crinetics Pharmaceuticals has 337 Employees.(i)
  • Crinetics Pharmaceuticals grew their employee count by 31% last year.

Crinetics Pharmaceuticals's People

NameTitleEmail/Phone
1
Chief Staff to the CEOReveal Email/Phone
2
VPReveal Email/Phone
3
VP, Investor Relations and CommunicationsReveal Email/Phone
4
VP, BiologyReveal Email/Phone
5
VP, Metabolic DiseasesReveal Email/Phone
6
VP Global Product LeadershipReveal Email/Phone
7
VP Market AccessReveal Email/Phone
8
VP Drug Metabolism and PharmacokineticsReveal Email/Phone
9
General CounselReveal Email/Phone
10
VP Human ResourcesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Crinetics Pharmaceuticals?

Neuropeptide Receptor Targeted Therapeutics for the Treatment of Endocrine Diseases and Cancers. We are driven by a passion for drug-hunting and tempered by a post-recession startup culture. Our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$446M

Total Funding

337

Number of Employees

$2.4M

Revenue (est)

31%

Employee Growth %

$1.1B

Valuation

N/A

Accelerator

Crinetics Pharmaceuticals News

2022-04-19 - Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Forecasted to ... Defense World

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Forecasted to ... Defense World

2022-04-13 - Crinetics Pharmaceuticals Announces Pricing of Underwritten ... GlobeNewswire

Crinetics Pharmaceuticals Announces Pricing of Underwritten ... GlobeNewswire

2022-03-30 - Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year ... GlobeNewswire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year ... GlobeNewswire

2021-10-28 - Radionetics Oncology Launches with $30M Investment

Photo Courtesy of Crinetics San Diego-based Crinetics Pharmaceuticals focuses on discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Radionetics Oncology, a pharmaceutical company developing radiotherapeutics, launched with $30 m ...

2021-10-25 - Crinetics Pharmaceuticals : Announces Closing of Public Offering of Common Stock

SAN DIEGO - October 25, 2021 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that is has closed it ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$85.2M3398%N/A
#2
$114.4M3393%N/A
#3
$104.1M3400%N/A
#4
$123.6M3416%N/A
#5
$123.6M3419%N/A

Crinetics Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2015-11-03$40.0MA5AM VenturesArticle
2018-03-15$63.5MBPerceptive AdvisorsArticle